Cover Image

Effects of Levothyroxine Treatment on Lipid Profile in Subclinical Hypothyroidism: A Randomized Clinical Trial

Karoon Shahebrahimi, Rozita Naseri, Tahereh Sadat Kalantarian, Mehrali Rahimi, Farid Najafi, Katayoun Derakhshandeh, Azam Sharifi

Background: Studies demonstrated controversial results on subclinical hypothyroidism (SCH) regarding lipid profile alteration with or without Levothyroxine treatment. The purpose of this study is to investigate the effects of Levothyroxine on serum lipids in SCH. Materials and Methods: One hundred patients with SCH referred to Taleghani hospital in Kermanshah were recruited and randomly assigned into the intervention or the control group. Patients in intervention group received Levothyroxine 50-75 micrograms for three months. Patients in control group received the same placebo with the same dose and duration. Lipid profile was measured before and after the trial and the changes were compared between groups. (IRCT code: 138903244179N1). Results: Triglyceride, Total Cholesterol, LDL, HDL and Lipoprotein-A were measured before and after treatment. None of the factors showed significant difference either between or within groups, before and after the treatment (P<0.05). Conclusion: Treating with Levothyroxine does not have any clinically significant impact on lipid profile in SCH patients which indicates that we should not expect SCH patients to use Levothyroxine solely for lipid profile alternation, except those with other clinical indications for treatment.[GMJ.2015;4(2):72-77]

Levothyroxine; Subclinical Hypothyroidism; Cholesterol; Lipoprotein-A; LDL; HDL

Cooper DS. Subclinical hypothyroidism. N Engl J Med. 2001;345(4):260-5.

Fatourechi V. Subclinical hypothyroidism: an update for primary care physicians. Mayo Clin Proc. 2009;84(1):65-71.

Ichiki T. Thyroid hormone and atherosclerosis. Vascul Pharmacol. 2010;52(3-4):151-6.

Rodondi N, den Elzen WPJ, Bauer DC, Cappola AR, Razvi S, Walsh JP et al. Subclinical Hypothyroidism and the Risk of Coronary Heart Disease and. JAMA. 2010;304(12):1365-74.

Reid C, Nelson MR, Shiel L, Chew D, Connor G, DeLooze F. Australians at risk: management of cardiovascular risk factors in the REACH Registry. Heart Lung Circ. 2008;17(2):114-8.

Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000;160(4):526-34.

MansourianAzad R, Ghaemi E, Ahmadi A. Serum lipid level alternation in subclinical hypothyroid patients in Gorgan (South east of Caspian sea). Journal of Chinese Clinical Medicine. 2008;4(3):4-5.

Kung AW, pang RW, Janu ED. Elevated serum lipoprotein (a) in subclinical hypothyroidism. Clin Endocrinol(oxf) 1995; 43(4): 443-4.

Christ-Crain M, Meier C, Guglielmetti M, Huber PR, Riesen W, Staub JJ, et al. Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial. Atherosclerosis. 2003;166(2):379-86.

Razvi S, Weaver JU, Vanderpump MP, Pearce SH. The incidence of ischemic heart disease and mortality in people with subclinical hypothyroidism: reanalysis of the Whickham Survey cohort. J Clin Endocrinol Metab. 2010;95(4):1734-40.

Yildirimkaya M, Ozata M, Yilmaz K, Kilinc C, Gundogan MA, Kutluay T. Lipoprotein(a) concentration in subclinical hypothyroidism before and after levo-thyroxine therapy. Endocr J. 1996;43(6):731-6.

Meier C, Stavis JJ, Roth CB. TSH controlled T4 therapy reduced cholesterol levels and clinical symptoms in subclinical hypothyroidism: A double blind placebo controlled trial. J Clin Endocrinol Metab 2001; 86(10): 4860-4.

Ganotakis ES, Mandalaki K, Tampakaki M, Malliaraki N, Mandalakis E, Vrentzos G et al. Subclinical hypothyroidism and lipid abnormalities in older women attending a vascular disease prevention clinic: effect of thyroid replacement therapy. Angiology. 2003;54(5):569-76.

Iqbal A, Jorde R, Figenschau Y. serum lipid levels in relation to serum TSH and the effect of thyroxine replacement on serum lipid levels in subjects with subclinical hypothyroidism: the Tromso study. J Intern Med. 2006;260(1):53-61.

Kalantari S, Heidarzade A. Thyroxine therapy improves serum lipoproteins and some clinical findings in patients with subclinical hypothyroidism. Int J of Endocrinol Metabol 2006; 4(2): 106-12.

Canturk Z, Cetinarslan B, Tarkun I, Canturk NZ, Ozden M. Lipid profile and lipoprotein (a) as a risk factor for cardiovascular disease in women with subclinical hypothyroidism. Endocr Res. 2003;29(3):307-16.

Carracio N, Ferrannini E, Monzani F. Lipoprotein profile in subclinical hypothyroidism and response to Levothyroxine replacement, a randomized placebo controlled study. J Clin Endocrinol Metab. 2002;87(4):1533-8.

Arem R, Escalante DA, Arem N, Morrisett JD, Patsch W. Effect of L-thyroxine therapy on lipoprotein fractions in overt and subclinical hypothyroidism, with special reference to lipoprotein(a). Metabolism. 1995;44(12):1559-63.

Tzotzas T, Karassas GE, Konstantinidis T, Bougoulia M. Changes in lipoprotein (a) levels in overt and subclinical hypothyroidism before and during treatment. Thyroid. 2000; 10(9): 803-8.

Clevidence BA, Judd JT, Schaefer EJ, Jenner JL, Lichtenstein AH, Muesing RA, et al. Plasma lipoprotein (a) levels in men and women consuming diets enriched in saturated, cis-, or trans-monounsaturated fatty acids. Arterioscler Thromb Vasc Biol. 1997;17(9):1657-61.

Vierhapper H, Nardi A, Grosser P, Raber W, Gessl A. Low-density lipoprotein cholesterol in subclinical hypothyroidism. Thyroid. 2000;10(11):981-4.

Moradi S, Hedayati M. Effects of Levothyroxine treatment on clinical and biochemical variables in patients with subclinical hypothyroidism. Iranian J of Endocrinol Metabol 2004; 6(1): 27-37.

Refbacks

  • There are currently no refbacks.